Cost-effectiveness of MR-mammography vs. conventional mammography in screening patients at intermediate risk of breast cancer

• Verfasst von: Kaiser, Clemens G. [VerfasserIn]
• Verfasst von: Dietzel, Matthias [VerfasserIn]
• Verfasst von: Vag, Tibor [VerfasserIn]
• Verfasst von: Froelich, Matthias F. [VerfasserIn]
• Titel: Cost-effectiveness of MR-mammography vs. conventional mammography in screening patients at intermediate risk of breast cancer
• Titelzusatz: a model-based economic evaluation
• Verf.angabe: Clemens G. Kaiser, Matthias Dietzel, Tibor Vag, Matthias F. Froelich
• E-Jahr: 2021
• Jahr: March 2021
• Umfang: 7 S.
• Fussnoten: Gesehen am 16.08.2021
• Titel Quelle: Enthalten in: European journal of radiology
• Ort Quelle: Amsterdam [u.a.] : Elsevier Science, 1990
• Jahr Quelle: 2021
• Band/Heft Quelle: 136(2021), Artikel-ID 109355, Seite 1-7
• ISSN Quelle: 1872-7727
• DOI: doi:10.1016/j.ejrad.2020.109355
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: Breast cancer
• Sach-SW: Cost-effectiveness
• Sach-SW: Intermediate risk
• Sach-SW: Mammography
• Sach-SW: MR-Mammography
• Sach-SW: Screening
• K10plus-PPN: 1767110545

Abstract

Purpose - The aim of this study was to analyze the cost-effectiveness of screening patients of intermediate risk of breast cancer with MR-Mammography (MRM) versus conventional mammography (XM). - Method - A decision model for both diagnostic modalities and a subsequent markov model for the simulation of follow-up costs and outcomes was developed. Input parameters were acquired from published literature for this markov modelling study. The expected cumulative costs and outcomes were calculated for both modalities in a 30-year timeframe in US-dollar ($) and quality-adjusted life years (QALYs). A deterministic sensitivity analysis and a probabilistic sensitivity analysis incorporating 30,000 Monte Carlo iterations were performed to investigate the model stability. - Results - In total, XM with its consecutive treatments resulted in total costs of $ 5,492.68 and an average cumulative quality of life of 18.87 QALYs, compared to MRM with costs of $ 5,878.66 and 18.92 QALYs. The corresponding incremental cost-effectiveness ratio (ICER) for MRM was $ 8,797.60 per QALY - distinctly below international willingness-to-pay thresholds for cost-effectiveness. The results were confirmed within the limits of the sensitivity analyses. - Conclusions - In patients with intermediate risk for breast cancer due to their dense breast tissue, two-yearly screening with MRM may be considered as cost-effective.